(Total Views: 296)
Posted On: 04/09/2018 4:38:37 PM
Post# of 72446
I disagree that cash on hand is "the market's" concern about this company.
There are MANY, MANY small biotechs that haven't gotten even one clinical trial into Phase 2 (and in some cases, haven't even commenced a clinical trial).
Yet they have larger market caps. Many of them also have tremendous debt. IPIX is in a much better situation in many ways than a typical small biotech.
The "market" is not what is holding this stock down. Relentless bashing, misinformation and disinformation, and attempts by shorts to manipulate the stock -- that's why the stock is nowhere near the value it should have, for just ONE of our many successful clinical trials.
The market isn't telling us it doesn't like the stock. The market doesn't even really know about the stock. It's the result of a concerted and continuing attack.
And the attackers know that their number is about to be up.
There are MANY, MANY small biotechs that haven't gotten even one clinical trial into Phase 2 (and in some cases, haven't even commenced a clinical trial).
Yet they have larger market caps. Many of them also have tremendous debt. IPIX is in a much better situation in many ways than a typical small biotech.
The "market" is not what is holding this stock down. Relentless bashing, misinformation and disinformation, and attempts by shorts to manipulate the stock -- that's why the stock is nowhere near the value it should have, for just ONE of our many successful clinical trials.
The market isn't telling us it doesn't like the stock. The market doesn't even really know about the stock. It's the result of a concerted and continuing attack.
And the attackers know that their number is about to be up.
(5)
(0)
